変異RASによるGTP水解の薬理学的回復
Antonio Cuevas-Navarro1, Yasin Pourfarjam1, Feng Hu1
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature
|October 30, 2024
まとめ
新しいトライコンプレックス阻害剤は,GTPase活性を回復することによって,RAS変異がんに対する新しい治療戦略を提供します. これらの分子接着剤は,GTPの水解を刺激し,がん細胞の増殖を抑制するためにサイクロフィリンA (CYPA) を採用します.
科学分野:
- 腫瘍学
- 分子生物学
- 薬物の発見
背景:
- RAS プロトオンコゲン (KRAS,NRAS,HRAS) は毎年約340万人のがん患者で頻繁に変異します.
- RASの変異はGTPaseの活性を低下させ,制御不能な細胞シグナル伝達と増殖につながります.
- RAS変異体を標的とした以前の治療戦略は失敗した.
研究 の 目的:
- RAS変異がんに対する新しい治療方法として,トリコンプレックス阻害剤の可能性を調査する.
- これらの阻害剤の作用の二重メカニズムを解明する.
主な方法:
- RASの活性状態にサイクロフィリンA (CYPA) を誘導するために設計されたトライコンプレックス阻害剤を使用した.
- これらの阻害剤がRASエフェクター結合とGTP水解に及ぼす影響を研究した.
- 薬物結合CYPA複合体によるRAS残基の変異特有の調節を分析した.
主要な成果:
- トライコンプレックス阻害剤は,RASエフェクター結合を阻害し,GTP水解を刺激する二重メカニズムを示した.
- 薬剤結合のCYPA複合体はRASスイッチIIモチーフの残基を調節し,GTPの水解を変異特異的に促進した.
- GTPase活性刺激に敏感なRAS変異体は,治療に対するより高い感受性を示した.
結論:
- GTP水解の薬理学的刺激は,特定のRAS変異体に対する三複合阻害剤の治療効果を強める.
- この研究は,突然変異したRAS GTPaseの活性を増強することによって,癌の成長を抑制する治療薬の開発のための基礎を確立しています.
関連する概念動画
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
GTPases and their Regulation
8.3K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒ small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
Large G-proteins,...
8.3K
Activation and Inactivation of G Proteins
6.8K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
6.8K
Rab Proteins
3.9K
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
3.9K
GPCR Desensitization
5.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.8K


